Key Highlights

  • Acumen Pharmaceuticals is trading down 85.77% at $0.33 after its Phase 2 Alzheimer's trial missed the primary endpoint.
  • ProMIS Neurosciences is trading down 42.60% at $6.36 with no company-specific announcement identified.
  • Alphatec Holdings is trading down 34.04% at $7.50 as full-year Revenue guidance fell to about $862 million.
  • Davion Healthcare is trading down 28.25% at $1.93 after listing on Nasdaq on Oct 22, 2026.
  • iTonic Holdings is trading down 21.41% at $2.24, below its prior 52-week low of $2.33.

Which Healthcare Stocks Are Falling the Most Today?

Five healthcare names led the decliners on Oct 30, 2026, with drops ranging from 21.41% to 85.77%. The ranking orders them by percentage decline, and the bases differ sharply: prices run from $0.33 to $7.50, and several prior closes cited below are derived from price and move rather than confirmed.

Acumen Pharmaceuticals (NASDAQ:ABOS) is trading down 85.77% at $0.33 after its Phase 2 Alzheimer's study failed. ProMIS Neurosciences (NASDAQ:PMN) is trading down 42.60% at $6.36, and no ProMIS-specific announcement was identified. Alphatec Holdings (NASDAQ:ATEC) is trading down 34.04% at $7.50 after a third-quarter revenue shortfall and a lower full-year outlook.

Davion Healthcare (NASDAQ:DAVI) is trading down 28.25% at $1.93, with no new announcement identified, and iTonic Holdings (NASDAQ:ITOC) is trading down 21.41% at $2.24, also without an identified catalyst. Only two of the five have a clearly identified company trigger.

The five stories differ in kind: one is a failed clinical trial, one an Earnings shortfall, and three are declines that the available reports cannot tie to a specific announcement. Each section below sticks to what those reports state and flags figures that remain unverified.

1. Acumen Pharmaceuticals: why is the stock down 85.77% today?

Acumen is trading down 85.77% at $0.33, which implies a prior close near $2.32 (derived). The company reported that its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease missed its primary endpoint, the iADRS score at 18 months, at both the 35 mg/kg and 50 mg/kg doses.

Key secondary endpoints, including CDR-SB, also failed to reach significance, even though amyloid PET imaging showed plaque reductions. Amyloid-related imaging abnormalities with edema occurred in about 10% of treated participants in the 542-person study.

Acumen said it will stop developing sabirnetug and evaluate strategic options. Cash stood at $110.2 million as of June 30, 2026, and a Market Value near $24 million (calculated from 72.3 million shares) sits well below that.

2. ProMIS Neurosciences: why is the stock down 42.60% today?

ProMIS is trading down 42.60% at $6.36, implying a prior close near $11.08 (derived). No ProMIS-specific announcement was identified. On the same day Acumen reported a failed Phase 2 trial of an antibody aimed at the same type of target, toxic amyloid Beta oligomers, though any link between the two moves is unconfirmed.

ProMIS develops antibodies against toxic misfolded proteins, led by PMN310. Its PRECISE-AD Phase 1b study enrolled 144 patients, with unblinded topline data expected in the first quarter of 2027. Cash was $53.4 million at June 30, 2026, which management expects to fund operations through 2027.

The second-quarter net loss was $11.7 million, or $1.28 per share. A market value near $57 million is a calculation using a data provider share count.

3. Alphatec Holdings: why is the stock down 34.04% today?

Alphatec is trading down 34.04% at $7.50, near the low end of a 52-week range of $6.82 to $23.29 from a data provider. The company reported third-quarter results on Oct 29, 2026, with revenue up 13% to $221 million, which it said fell short of expectations mainly because of lower Biologics attachment.

Full-year revenue is now expected near $862 million, compared with about $890 million in the February outlook as cited in reference material. Free Cash Flow guidance fell to about $10 million from at least $20 million.

Not all of the update was negative: adjusted EBITDA guidance rose to about $137 million, and the quarterly adjusted EBITDA Margin was 17.3%. Alphatec is a spine-focused medical device company.

4. Davion Healthcare: why is the newly Listed Stock down 28.25%?

Davion is trading down 28.25% at $1.93, and no company-specific announcement was identified. Its shares were slated to start trading on the Nasdaq Global Market on Oct 22, 2026 through a direct listing, which does not raise new capital.

A data provider showed a prior close of $6.00 on Oct 23 and about $4.04 on Oct 26, figures that are unverified. The Irish company develops non-invasive at-home screening tools, led by the BreastCheck test.

Davion is pre-revenue and reported an operating loss of about 0.8 million euros for 2025, per a secondary report. About 25 million shares imply a market value near $48 million (calculated). Sources also disagreed on who holds the chief executive role.

5. iTonic Holdings: why is the stock down 21.41% below its 52-week low?

iTonic is trading down 21.41% at $2.24, below its prior 52-week low of $2.33, and no company announcement explaining the move was identified. The screenshot ticker did not match any listing, so the NASDAQ:ITOC symbol is used here.

A 16-for-1 share consolidation took effect on Oct 6, 2026, cutting Class A shares from about 109.4 million to 6.8 million. Nasdaq had set an Oct 19, 2026 deadline to restore a $1.00 minimum bid, and confirmation of compliance was not found.

The Beijing-based Business sells brachytherapy planning software. Revenue was $523,031 in 2025, and net loss figures conflict between $8.92 million trailing and about $5.10 million for 2025.

Healthcare Slide Scorecard: Average Drop, Spread and Price Ratio

The average decline is 42.41% (calculated), but the group is lopsided: the spread between Acumen's drop and iTonic's is 64.36 percentage points (calculated). Alphatec's $7.50 price is about 22.7 times Acumen's $0.33 (calculated).

Bases differ widely, and the largest move comes from a binary trial readout. Alphatec's drop follows earnings, while ProMIS, Davion and iTonic have no confirmed company trigger.

Two of the three unexplained decliners, Davion and iTonic, are tied to share structure events, a direct listing and a reverse split, which the singles describe as context rather than a proven cause. The ProMIS drop coincides with Acumen's trial result, a timing link that has not been confirmed.

What to Watch Next: Biomarker Data, Trial Readouts and Listing Updates

Acumen expects additional fluid biomarker and imaging data in the coming weeks, with no date given. ProMIS expects all patients to finish 12 months of dosing by the fourth quarter of 2026, and unblinded PRECISE-AD data in the first quarter of 2027.

No dated release was identified for Alphatec, Davion or iTonic beyond their next periodic reports. Investors will watch for the first public filings from Davion and any confirmation of iTonic's Nasdaq compliance after the Oct 19, 2026 deadline.

Alphatec investors will look for evidence that biologics attachment recovers, and for delivery against the trimmed revenue and cash flow targets. Any further detail from Acumen on cash conservation or a revised runway would also be a reference point, given the strategic review.